ArticleMolecular psychiatry2026
Hippocampal neuronal progranulin mediates estrogen‑deficiency‑induced affective vulnerability and lysosomal-autophagic dysfunction.
Article in Molecular psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Trends in Depression and Its Association With Gallstones: Evidence From NHANES With Exploration of Mediating Pathways.Depression and anxiety · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
Perimenopausal women typically face a heightened risk of emotional disturbances, including anxiety and depression. The estrogen decline increases vulnerability to mood disorders, but the molecular mechanisms underlying stress resilience remain unclear. Here, we identify hippocampal neuronal progranulin (PGRN), a secreted neuroprotective glycoprotein, as a key regulator of affective resilience under estrogen-deficient conditions. Ovariectomy (OVX) reduces hippocampal neuronal PGRN expression and induces anxiety- and depression-like behaviors, whereas estradiol supplementation restores both PGRN levels and behavior. Adeno-associated virus (AAV)-mediated overexpression of PGRN alleviates affective deficits across OVX, 4‑vinylcyclohexene diepoxide (4-VCD)-induced ovarian failure, and natural aging models, while neuronal, but not microglial, Grn deletion exacerbates stress susceptibility. Mechanistically, PGRN restores lysosomal protease activity, normalizes autophagic flux, activates AMP-activated protein kinase (AMPK) phosphorylation, and rescues mushroom spine loss, thereby restoring cellular and synaptic homeostasis. Intracerebral recombinant PGRN rescues OVX‑induced behavioral deficits, and the blood-brain barrier (BBB)-permeable fragment granulin-E (GRN‑E) confers similar protection after systemic administration. Collectively, these findings demonstrate that hippocampal neuronal PGRN links estrogen signaling to lysosomal-autophagy pathways and synaptic plasticity, and highlight PGRN or its active fragments as promising therapeutic targets for perimenopausal depression and anxiety.
Identifiers
42533037What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.